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Title: Non-invasive prenatal testing for congenital heart disease – cell-free nucleic acid and
protein biomarkers in maternal blood
Abstract
Context: Congenital heart disease (CHD) is the most common fetal malformation. Prenatal
ultrasonography is routinely applied for the screening of CHD but many factors influence its
diagnostic accuracy. The introduction of new biomarkers could facilitate the identification of
high-risk pregnancies.
Objective: In our review, our aim was to collect expression studies of cell-free nucleic acids
and proteins in maternal circulation. Syndromic CHDs which can be detected by non-invasive
prenatal testing (NIPT) techniques were also discussed.
Methods:PubMed and Web of Science databases were screened for studies where the levels
of potential CHD biomarkers were measured in maternal blood samples. Available NIPT tests
were collected from the providers’ resources.
Results:There are nine CHD-associated chromosomal abnormalities, five aneuploidies, and
four microdeletions, which are included in NIPT panels.We found eight articles from which five
included the analysis of specific cell-free RNA expression and three measurements of protein
levels.
Conclusion: Most of the common heart-related chromosomal aberrations can be diagnosed by
NIPT. Specific cell-free RNAs and circulating proteins seem to be potential biomarkers for
fetal CHDs. The application of these new biomarkers could improve the detection rate at early
pregnancy, making it possible to provide optimal perinatal and perioperative management.
Keywords:congenital heart disease, maternal circulation, cell-free nucleic acids, NIPT,
biomarkers
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Introduction
Congenital heart defects (CHD) are the most common congenital malformations with an
incidence of 4-10/1000 live births [1]. Although the pathogenesis of CHD has been extensively
studied, the etiology of these malformations is still not clear. CHD remains a serious problem
accounting for 30% to 50% of mortality caused by congenital disorders among infants [2] and
half of the live birth cases requires one or more surgical procedures in the neonatal period and
childhood [3]. In certain types of fetal cardiac anomalies, early prenatal diagnosis may reduce
postnatal morbidity and mortality, by providing optimal perinatal and perioperative management
[4].Improved outcome was reported for hypoplastic left heart syndrome (HLHS), transposition
of the great arteries (TGA) and coarctation of the aorta (CoA) if the prenatal diagnosis had been
available [5–7].
Prenatal ultrasonography is the most widely available diagnostic test for fetal CHD but
many factors influence its diagnostic accuracy, hence the efficacy of prenatal ultrasound.
Unfortunately, detailed fetal echocardiography is limited to a few specialized centers, thus
low-risk pregnancies are not routinely screened. The four-chamber view is the gold-standard
screening view, on which the bulk of the cardiac lesions manifests alterations, however, other
major abnormalities show no sign of disease. Due to the adaptive fetal circulation, one side
of the heart can compensate for aberrations present in the other side, which hampers the
possibility of detection. Particular cardiac abnormalities present diagnostic difficulties, even in
specialized units. If CHD cannot be detected during the ultrasonography examinations, severe
comorbidities, such as chromosomal abnormalities, can remain also undiagnosed [8].
Risk factors for CHD include increased nuchal translucency (NT), fetal arrhythmias, major
extracardiac anomalies, maternal factors (e.g. metabolic conditions, maternal infections, etc.)
and genetic predisposition among others [9]. Nevertheless, the majority of CHD cases occurs
in the low-risk population, which emphasizes the importance of identifying factors that assign
pregnancy to the high-risk group of CHD [10]. In our review, our aim was to collect and
discuss expression studies of cell-free nucleic acids and proteins in maternal circulation, which
reveal new opportunities for CHD research and diagnosis.The introduction of new biomarkers
could facilitate the identification of high-risk pregnancies, thereby enabling a better diagnostic
efficacy.
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Clinical significance
Prenatal ultrasonography is routinely applied for the screening of fetal CHD but many
factors influence its diagnostic accuracy. Detailed fetal echocardiography is limited to a few
specialized centers, thus low-risk pregnancies are not routinely screened. The introduction of
new biomarkers could facilitate the identification of high-risk pregnancies, thereby enabling a
better diagnostic efficacy of CHD. Expression studies of cell-free nucleic acids and proteins
in the maternal circulation reveal new opportunities for CHD research and diagnosis. The
application of these new biomarkers could improve the detection rate at early pregnancy, making
it possible to provide optimal perinatal and perioperative management.
1.
Circulating cell-free nucleic acids (cfNA)
cfNAs can be found in the bloodstream, where they circulate freely, bound to lipoprotein
molecules or encapsulated within extracellular vesicles [11]. These DNA and different kind
of RNA molecules are thought to originate from apoptotic and necrotic cells that release their
contents into the circulation during their degradation [12]. cfNAs offers a non-invasive approach
to the early diagnosis of a wide range of clinical disorders.
The detection of circulating cfNAs in maternal blood has opened the door for non-invasive
prenatal screening, avoiding the necessity of risk-associated invasive procedures including
amniocentesis and chorionic villus sampling. Fetal-specific cfNAsare originated primarily from
the trophoblast layer of the placenta, which is in direct contact with the maternal circulation.
Placenta-derived cfNAscan be detected in the bloodstream from the 7thweek of pregnancy with
levelsincreasing as the gestation progresses and vanish quickly after birth[13]. Circulating cell-
free fetal DNA adds up toroughly 3–13% of the total cell-free maternal DNA during pregnancy.
Different types of placenta-specific RNAs also present in the maternal blood, including mRNA,
microRNA (miRNA) and long noncoding RNA (lncRNA) species.As free RNA molecules are
prone to degradation in theextracellular environment, it is believed that some type ofcirculating
RNAs is protected from nuclease activity by packaging into extracellular vesicles, making
complexes with lipoproteins or bounding to protein molecules[14].
Circulating cell-free DNA
Approximately 25 to 40% of CHD cases are related to genetic syndromes or associated with
other birth defects [15]. Some of the syndromic CHDs can be detected by NIPT techniques,
which enable high-throughput screening using next-generation sequencing (Table 1.)[16,17]. It
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is based on the analysis of circulating fetal-specific cell-free DNA in the maternal circulation to
screen for common chromosome conditions. Several NIPT companies offer very sensitive and
specific screening tests for aneuploidies, including trisomy 21, 13, 18, and sex aneuploidies.
CHD accompanies approximately 40-50% of trisomy 21 cases (Down syndrome) and is a
determining factor of survival [18]. Fetuses with trisomy 18 (Edward syndrome) or trisomy 13
(Patau syndrome) have a low rate of survival, and the majority of fetuses die before birth. In a
registry-based study performed in Europe, about 76–83% of live-born babies with trisomy 18,
and 51-64% of trisomy 13 cases 51–64% was reported to have CHD [19]. Turner syndrome
also called 45,X monosomy is associated with heart development abnormalities in 25-45% of
live births and more frequent if perinatal death cases are taken into account. In patients with
Klinefelter syndrome (47,XXY), there is a 50% incidence of CHD.
Congenital heart anomalies also occur in partial aberration syndromes, from which a few are
already included in NIPT companies’ screening panels: DiGeorge, 1p36, Wolf-Hirschorn, and
Jacobsen syndromes (Table 1.). DiGeorge syndrome, also known as 22q11.2 deletion syndrome
is considered as the most common human microaberration.
Circulating cell-free mRNA
Apart from the well-known cell-free fetal DNA, different types of placenta-specific RNAs
could be applied as non-invasive markers for CHD (Table 2.). The RNA profile of chorionic
villous samples and intraembryonic mesoderm derivates, including heart and NT, are shown to
beanalogous during the first trimester of pregnancy [20]. Arcelli et al. hypothesized that aberrant
expression of placental protein-coding genes related to cardiogenesis can be measured in the
maternal circulation [21]. In the first stage of their study, they screenedplacental mRNA profile
of women bearing fetus with CHD and healthy pregnant controls. They found that the levels of
MAP4, MYL7, P4HA2, PAPP-A, SAV1, TNXB, and TXN were altered in the patient group.In the
second stage of the study, aberrant mRNA expression was validatedin 2nd-trimester maternal
plasma samples for SAV1, TXNB, PAPP-A, TXN, and MYL7. The calculated the sensitivities
were 95%, 94%, 79%, 45%, and 42% at 10% false positive rate (FPR), respectively.Both the
developmental and validation modelCHD groupsincluded different kinds of lesions. In another
study from the same group, Nanostring technology was applied for the identification ofaberrant
gene expression in 2nd-trimester maternal plasma samples, and top findings were subsequently
measured by qPCR.The pool of six differently expressed genes including FALZ, PAPP-A,
PRKACB, SAV1, STK4, and TNXB2 was found to have a 66.7% detection rate at 10% FPR for
CHD [22].
Circulating cell-free microRNA
Data on the use of circulating microRNAs (miRNAs) as biomarkers of several diseases
are emerging. miRNAs are evolutionary conserved, small (20-26 nucleotides), non-coding
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RNA molecules that play an important role in the regulation of eukaryotic gene expression.
miRNAs participate in the fine-tuning of several fundamental biological processes. miRNA
expression profile changes during heart development [23] as well as the progression of heart-
related conditions, indicating that aberrant miRNA profile is involved in cardiovascular diseases
[24]. The possibility of using miRNAs to investigate the consequences of CHDs in children and
adults has also recently become an intensively researched field [25].
Cell-free miRNAs are shown to be quite stable in the circulation and they are also resistant
to adverse physiological circumstances such as multiple freezing/thawing cycles, and extended
storage[26].Expression studies of heart development related miRNAs in maternal circulation
reveal new opportunities for CHD research and diagnosis.Consequently, it can be postulated
that these specific miRNAs of placental origin could be applied as potential biomarkers for
fetalCHD[27].Zhu et al. performed SOLiD sequencing to compare the miRNA profile of
pooled serum samples from women carrying afetus with CHD and healthy pregnant women.All
the affected cases were VSD, ASD, orToF. Following qPCR validation assays, they found
four miRNAs, namelymiR-19b, miR-22, miR-29c, and miR-375, which were significantly
upregulated in the patient groupwith an area under the receiver operating characteristic
curve (AUC)of 0.79, 0.671, 0.767 and 0.693, respectively.[28].Kehler et al found elevated
hsa-miR-99alevel as a possible biomarker for the detection of CHD by analyzing maternal
plasmasamples[29].The miR-99a/let7c miRNA cluster is located in the chromosome region
21q21.1 and has been shown to control cardiomyogenesis in embryonic stem cells[30].Lázár
et al. has also analyzed let-7c expression in the maternal circulation and found that similarly to
hsa-miR-99a, it is also overexpressedin cases of fetal cardiac malformations [31].
Circulating cell-free long noncoding RNA
Long noncoding RNAs (lncRNA) are more than 200 nucleotides long, poorly conserved,
and the majority of them is species and tissue-specific. Possible mechanisms by which lncRNAs
can alter gene expression include mRNA decay, mRNA stabilization, or miRNA sponge.
lcnRNAs play a major role in the regulation of organ development, organ physiology, and
pathophysiology. In the fetal heart, lncRNAs are associated with genes involved in development
and programming [32]. They are known to be differentially activated at the fetal and postnatal
stages of heart development [33]. However, no individual human lncRNA has been causally
associated with CHD until now. Nevertheless, a recent study compared the expression profiles of
cardiac tissue from fetuses with VSD, one of the most common CHDs, and normal hearts [34].
More than 1500 lncRNAs were differentially expressed in hearts with VSD at the gestational
age between 17 and 20 weeks.
CHD associated lncRNAs were detected in the placenta, therefore circulating lncRNAs may
be utilized as early non-invasive biomarkers of CHD, similarly to other types of RNAs. To
explore the clinical utility of lncRNAs as biomarkers to predict fetal CHD in pregnant women,
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Gu et al screened the lncRNA profile by microarray technology, and the significant findings
were further investigated by Gene Ontology, pathway and network analysis. The disease group
included only VSD, ASD, and ToF samples. The differential expression of the top lncRNAs
was validated by qPCR and ROC curves were calculated.They found that ENST00000436681
and ENST00000422826 were upregulated, while AA584040, AA709223, and BX478947 were
downregulated in plasma samples of the affected group, with AUC values calculated as 0.892,
0.817, 0.755, 0.882, and 0.886, respectively [35].
Circulating protein molecules
Circulating protein molecules that have been applied in the prenatal setting for a long
time, are also offers a possibility for CHD screening. Llurba et al suggest that in case of
CHD, an imbalance of angiogenic-antiangiogenic factors present in both the maternal and
fetal circulation. In their first study, they proposed PIGF as a first-trimester biomarker for the
screening of conotruncal and valvular defects [36]. In the second study, angiogenic factors
and hypoxia markers were evaluated in fetal heart, umbilical cord and maternal blood samples
collected in the second and third semesters [37]. VEGF-A, s-Flt1, HIF-2α, HO-1, SOD-1 mRNA
expression was significantly elevated in affected fetal heart samples compared to controls, and
surprisingly no difference was measured in HIF-1α and PlGF. In the circulation of women
carrying CHD fetus, PlGF levels were significantly lower and sFlt-1 levels were significantly
higher. Curti et al performed a similar study on 3rd-trimester plasma samples using the Alere
PlGF Test, and they found that in line with the previous results, the PlGF concentration measured
in the affected group was significantly lower than in the control samples [38].
Chen et al. implementedserum proteomics analysis for exploringcirculating biomarkers
of fetal CHD in maternal blood[39].In the discovery phase, they performedshotgun
quantitative proteomics applying iTRAQ(isobaric Tagging for Relative and Absolute
Quantification)approach for comparing protein profiles of pooled serum samples in the affected
and control groups.The top findings were validated with MRM-MS and were further evaluated
in a large independent cohort using ELISAmethod. They identified a biomarker panel consisting
of cytoskeleton pathway proteins (LMNA, FLNA, TPM4, and ACTG1)all of which were
significantly lower in CHD maternal serum comparing to healthy controls. The combination
of the four candidates resulted in an AUC of 0.938 (95% CI, 0.905-0.970), and the sensitivity
and specificity were 95.0% (95% CI, 86.1%- 99.0%) and 83.9% (95% CI, 76.0%- 90.0%),
respectively.Interestingly, theyfound that serum level of LMNA was very low in nonpregnant
women and increased with gestation age in pregnant women, suggesting a specific role
inpregnancy.
Discussion
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Fetal-specific cfNAs are originated from the placenta and can be found in the maternal
circulation during pregnancy. Apart from the well-known cfDNA, different types of placenta-
specific RNAs also present in the maternal blood, including mRNA, miRNA, and lncRNA.
Farina and Arcelli suggest that the analysis of the placenta-derived RNA species could be
applied as a non-invasive screening tool of CHD [40]. Placentally expressed genes related to
cardiogenesis can be detected in the maternal circulation, which may reflect the development
of the birth defect, hence gives an opportunity for investigation during early pregnancy.
Comparative proteomic analysis has been widely used in discovering new biomarkers for
various pregnancy complications and fetal abnormalities. Dysregulation of these proteins not
only opens the door for the development of new non-invasive biomarkers for CHDs but also
reflects the molecular origins of the disease. Disturbed angiogenesis has been implicated in
abnormal heart development and placentation. Both pregnant women bearing fetuses with CHD
and women affected by preeclampsia (PE) often show angiogenic imbalances. Angiogenic
factors including s-Flt1 and PlGF were found to be dysregulated in CHD and what is more,
these proteins are routinely used in the first-trimester screening of PE. Boyd et al. conducted
a register-based cohort study and they found that linked pathophysiological mechanisms may
be implicated in some CHDs and preterm PE [41]. Based on the strong associations across
pregnancies they suppose that PE predisposes to the development of CHDs. Cytoskeletal
proteins are essential for the structure and function of the cardiac myocytes, and some of them
are probably pregnancy-specific. The study of Chen et al. indicated that dysregulation of these
proteins might reflect disturbance of cardiogenesis and could be applied in the screening of
CHD pregnancies. However, further studies are needed to understand the exact mechanism for
the downregulation of cytoskeletal proteins in heart anomalies. The advantages and limitations
of the application of different cf-NA and protein biomarkers as NIPT tools are summarized in
Table 3.
Conclusion
In spite of that CHDs are the most common group of birth defects, current prenatal
screening is not able to detect high-risk cases effectively. Expression studies of cfNAs and
proteins in the maternal circulation reveal new opportunities for CHD research and diagnosis.
Most of the common heart-related chromosomal aberrations can be diagnosed using NIPT
methodology by the analysis of cell-free fetal DNA. Based on our review, cell-free RNAs and
circulating proteins seems to be potential biomarkers for fetalCHDs and could be used to identify
high-risk pregnancies to be addressed for fetal echocardiography.The application of these new
biomarkerscould improve the detection rate at early pregnancy, making it possible to provide
optimal perinatal and perioperative management.
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Abbreviations
ASD: Atrial Septal Defect
AS: Aorta Stenosis
AUC: Area Under the receiver operating characteristic Curve
AVSD: Atrioventricular Septal Defect
BAV: Bicuspid Aortic Valve
cfNA: cell-free Nucleic Acid
CHD: Congenital Heart Disease / Congenital Heart Defect
CoA: Coarctation of the Aorta
DORV: Double Outlet Right Ventricle
ELISA: Enzyme-Linked Immunosorbent Assay
FPR: False Positive Rate
HLHS: Hypoplastic Left Heart Syndrome
IAA: Interrupted Aortic Arch
iTRAQ: isobaric Tagging for Relative and Absolute Quantification
lncRNA: long noncoding RNA
mRNA: messenger RNA
miRNA: microRNA
MRM-MS: Multiple Reaction Monitoring Mass Spectrometry
MS: Mitral Stenosis
NIPT: Non-Invasive Prenatal Testing
NT: Nuchal Translucency
PDA: Patent Ductus Arteriosus
PS: Pulmonary Stenosis
ROC: Receiver Operating Characteristic
SOLiD: Sequencing by Oligonucleotide Ligation and Detection
TGA: Transposition of the Great Arteries
ToF: Tetralogy Of Fallot
VSD: Ventricular Septal Defect
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Syndrome CHD frequency1 CHD type2 NIPT panel3-8
Aneuploidies
Down syndrome
(Trisomy 21)
40-50% ASD, VSD, AVSD, ToF all
Edwards syndrome
(Trisomy 18)
90-100% ASD, VSD, PDA, TOF,
DORV, CoA, BAV
all
Patau syndrome (Trisomy
13)
80% ASD, VSD, PDA, HLHS all
Turner syndrome (45,X0) 25-35% CoA, BAV, AS, HLHS all
Klinefelter syndrome
(47,XXY)
50% PDA, ASD all
Microdeletions
DiGeorge syndrome
(22q11.2 deletion)
75% ToF, IAA-B, VSD,
truncus arteriosus, DORV
BGI, Sequenom,
Natera, Illumina,
Roche, Lifecodexx
Jacobsen syndrome
(11q23 deletion)
56% VSD, ASD, TA, DORV,
BAV, AS, HLHS, MS,
CoA
Sequenom
Wolf-Hirschhorn
syndrome (4p16.3
deletion)
50% ASD, PS, ToF, VSD, PDA BGI, Sequenom,
Illumina
1p36 syndrome 35% Septal defects, PDA,
valvular abnormalities,
CoA, ToF,
cardiomyopathy
BGI, Sequenom,
Natera, Illumina
Table 1. Screening of chromosomal abnormality-relatd syndromic CHDs and available
NIPTpanels.
1[15]
2[42]
3[43]
4[44]
5[45]
6[46]
7[47]
8[48]
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Gestation Blood
component
Type of
biomarker
Potential biomarkers Diagnostic
measure
Methods Ref.
Sensitivity
20–22
weeks
Whole blood
(EDTA)
mRNA SAV1 ↑
TNXB ↑
PAPP-A ↑
TXN ↑
MYL7 ↑
95%
94%
79%
45%
42%
RT-PCR* [21]
19–24
weeks
Plasma mRNA PAPP-A ↑
PRKACB ↑
SAV1 ↑
STK4 ↑
TNXB2 ↑
18%
18%
28%
41%
33%
Nanostring
RT-PCR*
[22]
11-13
weeks
Plasma protein PLGF ↓ - ELISA* [36]
2nd-3rd
trimester
Plasma protein s-Flt1 ↑
PLGF ↓
- ELISA* [37]
AUC
22-26
weeks
Serum protein LMNA ↓
FLNA ↓
TPM4 ↓
ACTG1 ↓
0.867
0.766
0.760
0.760
iTRAQ
MRM-MS
ELISA*
[39]
18-22
weeks
Serum miRNA miR-19b ↑
miR-22 ↑
miR-29c ↑
miR-375 ↑
0.79
0.671
0.767
0.693
SOLiD
sequencing
RT-PCR*
[28]
2nd-3rd
trimester
Plasma miRNA miR-99a ↑ - RT-PCR* [39]
22-26
weeks
Plasma lncRNA ENST00000436681↑
ENST00000422826↑
AA584040 ↓
AA709223 ↓
BX478947 ↓
0.892
0.817
0.755
0.882
0.886
Microarray
RT-PCR*
[35]
Table 2. Potential cell-free RNA and protein biomarkers for CHD in the maternal circulation.
↑: overexpression, ↓: underexpression. *Applicable diagnostic tool
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Biomarkers Advantages Disadvantages
cf-DNA Standardized
High sensitivity
Translated into the clinic
Applicable only for specific CHD-related
chromosomal aberrations
cf-mRNA Reflect the status of intracellular
processes
Degradation, instability, low abundance
Detection difficulties
Low reproducibility
cf-miRNA Stable
Easily detectable
Tissue-specific expression
Extensively researched
Lacks validation, standardization, and
internal controls
Influencing factors (e.g. hemolysis)
Large sample-to-sample variability
cf-lncRNA Stable
Easily detectable
Tissue-specific expression
Lacks validation, standardization, and
internal controls
Large sample-to-sample variability
Protein Easily detectable
Cost-efficient
Usually not tissue-specific, can reflect the
disease state of any organ
Poor signal-to-noise ratio
Table 3. Advantages and disadvantages of circulating cf-NA and protein biomarkers in NIPT
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